Jingcao Huang

Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.

Therapeutic effect of 28-homobrassinolide on leukotriene synthesis in leukemia cells.

Epigenetic mechanism of survivin dysregulation in human cancer.

Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.

Young female patients with multiple myeloma have low occurrence of osteolytic lesion.

Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34 cells.

Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells.

Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors-a Study in Leukemia Cells.

SLC2A5 overexpression in childhood philadelphia chromosome-positive acute lymphoblastic leukaemia.

[Molecular Characteristics and Clinical Features of Adults with Fusions in Acute Myeloid Leukemia].

Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.

Wharton's jelly mesenchymal stem cell-based or umbilical vein endothelial cell-based serum-free coculture with cytokines supports the ex vivo expansion/maintenance of cord blood hematopoietic stem/progenitor cells.

PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells.

Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating .

High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates mA methylation of MYC mRNA.

Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.

Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.

ALCAM-EGFR interaction regulates myelomagenesis.

Minimal residual disease in multiple myeloma: current status.

Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing.

Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease.

ALCAM regulates multiple myeloma chemoresistant side population.

Dasatinib and interferon alpha synergistically induce pyroptosis-like cell death in philadelphia chromosome positive acute lymphoblastic leukemia.

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.

A novel immune prognostic model of non-M3 acute myeloid leukemia.

Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity.

Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.

Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.

RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.

Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.

Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.

Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib.